Built on a foundation that leverages over 20 years of North American venture capital experience, the Lumira Capital team has substantial experience helping to build transformational health and life science companies.
Our goal is to make investments in market leading companies and work in partnership with those companies to develop and implement strategies to build significant businesses that in turn allow us to generate profitable exits that maximize returns within a reasonable time frame.
As partners in our businesses we are committed to the success of our portfolio companies. We roll up our sleeves and work side by side with our entrepreneurs, their management teams and our syndication partners – leveraging our internal resources, knowledge networks, deep industry expertise and relationships, as well as our operational and leadership experience to help the businesses achieve their full potential.
141 Adelaide Street West, Suite 770,
Toronto, ON, CA. M5H 3L5
t.416.213.4223 f.416.213.4232
The funding of Canada’s biotech industry has changed drastically in recent years. Peter Van Der Velden of Lumira Capital discusses those changes and how his venture capital business is adapting…
Referring to the Canadian affiliate of Zimmer Biomet as a “trailblazer”, Dave O’Neil looks back on a successful 2017 for the musculoskeletal healthcare company in Canada. He describes how Zimmer…
Looking back on 40 years of commitment to Canada, Servier also celebrates 20 years of R&D activity in the country. On this two-fold anniversary, Frédéric Fasano highlights some of the…
Dwight Gorham, president and CEO of Pillar5 Pharma, discusses the unique positioning of the CDMO in the multi-dose preservative free sterile ophthalmics space and stresses the importance of anticipating market…
Despite its relative youth, Canada’s medical cannabis industry is already presenting some of the characteristics of the much more mature pharmaceutical industry. There is consolidation as well as the first…
Susanne Picard, founder and president at SPharm, speaks about how her passion for regulatory affairs led her to found her own consultancy in 1997 and how the company can look…
Having managed the Canadian affiliate of Otsuka from its infancy steps, Allison Rosenthal, general manager, highlights the affiliate’s feat to exceed expectations for the performance of each of its launches…
Having just announced the first collaboration between a medical cannabis company and a major pharmaceutical player, Tilray expects to launch its first co-branded product with Sandoz Canada by the end…
Looking back on three years of operations in Canada and nine months of approval of Ocaliva® for the rare non-viral liver disease PBC, Brian Canestraro, general manager of Intercept, is…
Lee Ferreira, newly-appointed general manager of Ferring Pharmaceuticals Canada, shares her excitement about the company’s transformative changes. She stresses the importance of conducting research in Canada in all areas of…
After 35 years in the pharmaceutical industry, Barry Fishman shares his excitement about heading one of Canada’s leading licensed cannabis producers. He explains how his experience in the world of…
Heather Chalmers, vice president and general manager of GE Healthcare Canada, shares the company’s increasing focus on incorporating applied intelligence and digital analytics in its portfolio of innovative solutions, and…
Lisa Purdy, who leads the healthcare & life sciences industry team in Canada and Kelley Dealhoy, global subject matter expert in life sciences M&A and external growth opportunities, discuss advantages…
See our Cookie Privacy Policy Here
